Home›Trial›NCT05599412
🔬NCT05599412RECRUITING

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

Study Summary

The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua

Conditions
Metastatic ALK+ Non Small Cell Lung Cancer
Interventions / Drugs
Lorviqua
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
F34/100
Study Details
Enrollment600 participants
Primary Completion—
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.189845+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.